Dr. Mark S. Shearman Net Worth

The estimated Net Worth of Mark S Shearman is at least $337 Thousand dollars as of 13 February 2023. Dr Shearman owns over 2,790 units of Editas Medicine Inc stock worth over $247,813 and over the last 9 years he sold EDIT stock worth over $88,788.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr Shearman EDIT stock SEC Form 4 insiders trading

Dr has made over 4 trades of the Editas Medicine Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,790 units of EDIT stock worth $26,979 on 13 February 2023.

The largest trade he's ever made was selling 5,145 units of Editas Medicine Inc stock on 15 June 2022 worth over $51,759. On average, Dr trades about 820 units every 137 days since 2015. As of 13 February 2023 he still owns at least 65,559 units of Editas Medicine Inc stock.

You can see the complete history of Dr Shearman stock trades at the bottom of the page.

Dr. Mark S. Shearman biography

Dr. Mark S. Shearman is the Exec. VP & Chief Scientific Officer at Editas Medicine Inc.

How old is Dr Shearman?

Dr Shearman is 61, he's been the Exec. VP & Chief Scientific Officer of Editas Medicine Inc since . There are 7 older and 10 younger executives at Editas Medicine Inc. The oldest executive at Editas Medicine Inc is Dr. George McDonald Church Ph.D., 67, who is the Co-Founder & Scientific Advisory Board Member.

What's Dr Shearman's mailing address?

Mark's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE, MA, 02141.

Insiders trading at Editas Medicine Inc

Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr, and Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.

What does Editas Medicine Inc do?

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Complete history of Dr Shearman stock trades at Applied Genetic Technologies Corp and Editas Medicine Inc

Editas Medicine Inc executives and stock owners

Editas Medicine Inc executives and other stock owners filed with the SEC include:

• Cynthia Collins,
  President, Chief Executive Officer, Director
• Charles Albright,
  Executive Vice President, Chief Scientific Officer
• Dr. Bruce E. Eaton Ph.D.,
  Exec. VP & Chief Bus. Officer
• Michelle Robertson,
  CFO, Principal Accounting Officer, Treasurer & Assistant Sec.
• David Scadden,
  Independent Director
• James Mullen,
  Independent Chairman of the Board
• Jessica Hopfield,
  Independent Director
• Andrew Hirsch,
  Independent Director
• Dr. Lisa A. Michaels M.D.,
  Exec. VP & Chief Medical Officer
• Akshay Vaishnaw,
  Independent Director
• James C. Mullen,
  Chairman, Pres & CEO
• Lisa Michaels,
  Executive Vice President, Chief Medical Officer
• Mark Mullikin,
  Investor Relations Officer
• Gad Berdugo,
  Chief Business Officer
• Harry Gill,
  Senior Vice President - Operations
• Michelle Robertson,
  Chief Financial Officer
• Dr. Gilmore O'Neill,
  Pres & CEO
• Charlene Stern J.D., Ph.D.,
  Exec. VP & Gen. Counsel
• Ron Moldaver,
  Investor Relations
• Dr. J. Keith Joung M.D., Ph.D.,
  Co-Founder & Scientific Advisory Board Member
• Dr. George McDonald Church Ph.D.,
  Co-Founder & Scientific Advisory Board Member
• Charlene Stern,
  Sr. VP & Chief Legal Officer
• Dr. Mark S. Shearman,
  Exec. VP & Chief Scientific Officer
• Harry R. Gill III,
  Sr. VP of Operations
• Dr. David R. Liu,
  Co-Founder & Scientific Advisory Board Member
• Dr. J. Keith Joung,
  Co-Founder & Scientific Advisory Board Member
• Dr. George M. Church,
  Co-Founder & Scientific Advisory Board Member
• Dr. Feng Zhang,
  Co-Founder & Scientific Advisory Board Member
• Douglas G. Cole,
  Director
• Katrine Bosley,
  President and CEO
• Kevin P Starr,
  10% owner
• Alexis Borisy,
  Director
• Alexandra Glucksmann,
  Chief Operating Officer
• Venture Management Co. Vi, ...,
  
• Ventures Fund Iv, L.P.Flags...,
  
• Kevin Bitterman,
  Director
• Gerald Frank Cox,
  Chief Medical Officer
• Ventures Fund Iv, L.P.Flags...,
  
• John Mendlein,
  Director
• Boris Nikolic,
  Director
• Andrew A. F. Hack,
  Chief Financial Officer
• Rock Ventures Iii, L.P.Thir...,
  
• Llc Bng0,,
  10% owner
• Bernadette Connaughton,
  Director
• Elliott M. Levy,
  Director
• Vickesh Myer,
  Chief Technology Officer
• Global Investors Lp Viking ...,
  
• Global Performance Llc Viki...,
  
• James E Deerfield Mgmt Iii,...,
  
• Baisong Mei,
  EVP, CHIEF MEDICAL OFFICER
• Mark S Shearman,
  EVP, CHIEF SCIENTIFIC OFFICER
• Meeta Chatterjee,
  Director
• Bruce Eaton,
  EVP, CBO AND CTO
• Emma Reeve,
  Director
• Erick Lucera,
  EVP, CHIEF FINANCIAL OFFICER
• Gilmore Neil O'neill,
  CEO
• Linda Burkly,
  EVP, CHIEF SCIENTIFIC OFFICER